期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

洛铂诱导肺腺癌HTB-56表达ERCC1及其意义初探 被引量：5

原文传递
导出
摘要 目的观察洛铂(LBP)作用下诱导肺腺癌HTB-56细胞株ERCC1的表达,并初步探讨ERCC1与肺癌LBP耐药之间的关系。方法采用RT-PCR方法检测不同浓度、不同作用时间LBP干预后人肺腺癌细胞株HTB-56 ECRR1的表达情况,并与其耐顺铂(DDP)细胞株HTB-56/DDP进行比较,分析ERCC1与LBP耐药之间的关系。结果 8μg/ml LBP作用24 h,HTB-56细胞中ERCC1 mRNA表达开始增高,随作用时间的延长,ERCC1 mRNA的表达逐渐增高,72 h组ERCC1 mRNA表达最强,为(63.17±4.32)%,是对照组的3.3倍。浓度为8μg/ml的LBP即可刺激HTB-56细胞中ERCC1基因水平上升,随LBP浓度的增加,ERCC1mRNA水平逐渐上升,64μg/ml组达高峰,为(69.30±4.88)%,为对照组的3.7倍。结论小剂量LBP作用随时间的延长,HTB-56细胞中ERCC1 mRNA表达量增加,推测ERCC1可能参与洛铂继发耐药的发生。
作者 高文斌 邓蓉 黄剑辉 王刚 吕金燕 李花妮 马建增 郑真真 方今女 高景山 姚娜
机构地区 大连大学附属中山医院肿瘤内科 延边大学医学部病理及病理生理学教研室 大连医科大学基础医学院
出处 《中华临床医师杂志（电子版）》 CAS 2012年第5期166-167,共2页 Chinese Journal of Clinicians(Electronic Edition)
基金 2010年度"CSCO-金港榄香烯肿瘤学研究生奖学助学基金"项目(J-2010-008)
关键词 肺肿瘤 HTB-56细胞株 HTB-56/DDP细胞株 洛铂 ERCC1基因
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献1

二级参考文献14

  • 1Le Chevalier T. For the IAL T Investigators. Result s of the Randomized International Adjuvant Lung Cancer Trial ( IAL T) : cisplatin -based chemotherapy (CT) vs no CT in 1867 patient s (pts) with resected non -small cell lung cancer (NSCLC) [ J]. Proc Am Soc Clin Oncol,2003,23:6a.
  • 2Winton TL, Livingston R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine and cisplatin in completely resected stage Ⅰb and Ⅱ non -small cell lung cancer[ C]. New Orleans 40th Annal Meeting of the American Society of Clinical Oncology,2004,7018.
  • 3Strauss GM, Hemdon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resected in stage Ⅰb non - small cell lung cancer ( NSCLC ) : report of Cancer and Leukemia Group B ( CALGB ) protocol 9633 [ J]. J Clin Oncol,2004,22 ( Suppl 14S) : 612.
  • 4Douillard JY, Rosell R, Delena M, et al. Phase Ⅲ adjuvant vinorelbine and cisplatin versus observation in completely resected ( stage Ⅰ - Ⅲ ) non - small cell lung cancer patients: final results after 70 - month median followup [ J ]. J Clin Oncol, 2005,23 ( Suppl 16s) : 624.
  • 5Pisters K , Vallieres E, Bunn PA, et al. Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin(PC) chemotherapy in early stage non- small cell lung cancer (NSCLC) :Follow -up on a phase Ⅲ trial [ J]. J Clin Oncol,2007.25 (18s) :7520.
  • 6Scagliotti G, Pastorino U, Vansteenkiste J, et al. A phase Ⅲ randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early - stage non - small cell lung cancer (NSCLC) : Follow - up data of Ch.E. S. T [ J ]. J Clin Oncol, 2008,26:7508.
  • 7Nieolson M, Gilligan D, Smith I, et al. Pre - operative chemotherapy in patients with resectable non - small cell lung cancer (NSCLC) : First results of the MRC LU22/NVALT/EORTC 08012 multi - centre randomised trial [ J ]. J Clin Oncal, 2007, 25 (18suppl) : 7518.
  • 8Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non - small cell lung cancer [J]. N Engl J ned,2002,346:92 -98.
  • 9Shepherd FA, Daneey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non - small cell lung cancer previously treated with platinum - based chemotherapy[J]. J Clin Oncol,2000,18(10) : 2095 -2103.
  • 10Gefitinib(Iressa) Lung Cancer ISEL trial shows no overall suivival advantage in a highly refractory population[ J]. Astrazeneca Press Relesase, 2004.

共引文献33

同被引文献50

  • 1陈昱丞,张明智,张旭东,周超锋,陈新峰,岳光星,杨黎,盛誉乔.抗微管类、铂类药物对人淋巴瘤细胞系体外敏感性实验及TUBB3、ERCC1表达的相关性分析[J].西安交通大学学报（医学版）,2012,33(5):539-543. 被引量：3
  • 2McKeage MJ. Lobaplatin: a new antitumour platinum drug [ J ]. Expert Opin Investig Drugs, 2001, 10( 1 ) : 119-128.
  • 3Kairi JK, Toth JW, Gusani N J, et al. Muhidisciplinary management of malignant pleural effusion [ J ]. J Surg Oncol, 2012,105 ( 7 ) : 731-738.
  • 4Katzenstein HM, Petricca S, Olson TA, et al. Intracavitary cisplatin therapy for pediatric malignancies[J]. Pediatr Blood Cancer, 2010, 55(3) : 452-456.
  • 5Perabo FG, Mtlller SC. New agents for treatment of advanced transitional cell carcinoma[J]. Ann Oncol, 2007, 18(5): 835.
  • 6Wang Z, Tang X, Yang X, et al. Lobaplatin induces apoptosis and arrests cell cycle progression in human cholangiocarcinoma cell line RBE[J]. Biomed Pharmacother, 2012, 66(3) : 161-166.
  • 7Dai HY, Liu L, Li SY, et al. Lobaplatin suppresses proliferation and induces apoptosis in the human colorectal carcinoma cell Line LOVO in vitro [ J]. Biomed Pharmacother, 2011, 65 ( 3 ) : 137- 141.
  • 8Engel JB, Martens T, Honig A, et al. Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple- negative p53-mutated breast cancers in vitro[ J]. Anticancer Drugs, 2012, 23(4) : 426-436.
  • 9Harstrick A, Vanhoefer U, Seeber S, et al. Drug interactions of 5- fluorouracil with either cisplatin or lobaplatin-a new, clinically active platinum analog in established human cancer cell lines [ J 1. Antieancer Drugs, 1997, 8(4) : 391-395.
  • 10Fiebig HH, Henb H, Vonpawel L, et al. Phase II clinical trim of lobaplatin(D219466) in pretreated patients with advanced small cell lung cancer[J]. Onkologie, 1996, 19: 328-332.

引证文献5

二级引证文献18

中华临床医师杂志（电子版）
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部